News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has awarded 10% owner Barry Canton a total of 319,332 restricted stock units (RSUs) on July 28, 2026. These RSUs cover Class A Common Stock, with some vesting 75% on October 16, 2026, and 25% on January 21, …
Sharemaestro market context Price above Trend Line 52 weeks -28.3% · Next-week setup negative 4.8%Ginkgo Bioworks Holdings, Inc. CEO Jason R. Kelly was granted two awards of restricted stock units (RSUs) on July 28, 2026. One grant is for 74,258 RSUs, vesting 75% on October 16, 2026, and 25% on January 21, 2027. The second grant is for …
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.7% in Ginkgo Bioworks Holdings, Inc. Class A stock. This amounts to 4,122,510 shares, with BlackRock's reporting business units holding sole voting power over 4,013,128 shares and sole dispositive power over …
This article provides a risk assessment for Pediatrix Medical Group Inc (MD), noting its current risk score of 5.98, ranking it 34 out of 75 in the Healthcare Providers & Services industry. The company has a beta value of 0.70, indicating it tends to …
Pediatrix Medical Group (NYSE: MD) had approximately 6,607 employees worldwide as of March 2026, marking a 3.3% decline from 2023 but a 0.1% increase year-over-year. The company is actively hiring, with 934 active job postings in 2026, a 46.9% increase from 2025. The workforce …
Bernstein Liebhard LLP reminds investors of the January 18, 2022, deadline to file a lead plaintiff motion in a securities class action lawsuit against Ginkgo Bioworks Holdings, Inc. The lawsuit, filed in the United States District Court for the Northern District of California, alleges …
Ginkgo Bioworks Holdings, Inc. Class A (9L40) reported revenues of €144.87 million last year, with the Cell Engineering segment contributing the most at €113.02 million. This was a decrease from the previous year's €168.
This article provides an overview of Pediatrix Medical Group Inc (MD)'s shareholder structure, detailing major institutional holdings and shareholder types. It lists top shareholders like BlackRock and Vanguard, their respective proportions, and also provides a historical look at institutional shareholding and recent shareholder activity. …
Pediatrix Medical Group, Inc. (NYSE: MD) reported total revenue of $1.91 billion USD last year. The majority of this revenue came from its Neonatal, Maternal-fetal and Other Pediatric Subspecialty Physician Services segment. The United States was the primary contributor to this revenue, accounting for …
This article provides a comprehensive cash flow statement for Pediatrix Medical Group Inc (MD), broken down into quarterly and annual data for operating, investing, and financing activities. It details various components like net income, capital expenditures, and changes in working capital, along with frequently …
This article analyzes Ginkgo Bioworks Holdings Inc. Class A (NYSE: DNA), highlighting weak sentiment across all horizons supporting a short bias. It details an exceptional 126.0:1 risk-reward setup targeting a 34.9% gain versus 0.3% risk. The analysis provides three institutional trading strategies (Position, Momentum …
Pediatrix Medical Group (MD) recently reported strong quarterly results which were well received, despite its long-term revenue growth averaging only 2.1% annually over the past five years and declining return on invested capital. This creates a tension between its current operational strength and future …
Ginkgo Bioworks (NYSE: DNA) CFO Steven P. Coen reported the vesting of 1,486 restricted stock units (RSUs) on July 16, 2026. Following this, he sold 752 shares of Class A Common Stock on July 17, 2026, at $7.903 per share. This sale was a …
Sharemaestro market context Price above Trend Line 52 weeks -28.3% · Next-week setup negative 4.8%Ginkgo Bioworks insider Steve Coen has filed a Form 144 notice to sell 752 Class A common shares through Fidelity Brokerage Services. These shares originated from restricted stock vesting as compensation. The filing also reports previous Class A stock sales by Coen on April …
Sharemaestro market context Price above Trend Line 52 weeks -28.3% · Next-week setup negative 4.8%Pediatrix Medical Group (MD) shares rose 7.3% following an impressive volume and investor optimism regarding the company's Q2 2026 update. The company confirmed stable payor mix and reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280-$300 million, with expected quarterly earnings of $0.57 per …
Healthcare sector analysts have provided insights on Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX). Mizuho Securities maintained a Hold rating on Pediatrix Medical Group with a $27.00 price target, while Wedbush maintained a Buy rating on Travere Therapeutics with a $61.00 price target. …
Pediatrix Medical Group (MD) has reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million after maintaining a stable second-quarter payor mix, following significant share price growth. While analysts view the stock as 11.7% overvalued based on growth and margin assumptions, …
Search by ticker symbol or company name and select a result to open its chart.